Accelerated gray and white matter deterioration with age in schizophrenia

VL Cropley; P Klauser; RK Lenroot; J Bruggemann; S Sundram; C Bousman; A Pereira; MA Di Biase; TW Weickert; CS Weickert; C Pantelis; A Zalesky

Journal article

Accelerated gray and white matter deterioration with age in schizophrenia

VL Cropley, P Klauser, RK Lenroot, J Bruggemann, S Sundram, C Bousman, A Pereira, MA Di Biase, TW Weickert, CS Weickert, C Pantelis, A Zalesky

American Journal of Psychiatry | AMER PSYCHIATRIC PUBLISHING, INC | Published : 2017

DOI: 10.1176/appi.ajp.2016.16050610

Abstract

Objective: Although brain changes in schizophrenia have been proposed to mirror those found with advancing age, the trajectory of gray matter and white matter changes during the disease course remain sun clear. The authors sought tomeasure whether these changes in individuals with schizophrenia remain stable, are accelerated, or are diminished with age. Method: Gray matter volume and fractional anisotropy were mapped in 326 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison subjects aged 20-65 years. Polynomial regression was used to model the influence of age on gray matter volume and fractional anisotropy at a whole-brain and voxel level. Bet..

View full abstract

University of Melbourne Researchers

Vanessa Cropley Author

Paul Klauser Author

Maria Di Biase Author

Christos Pantelis Author

Related Projects (4)

TOOLS FOR ANALYSING BRAIN IMAGING DATA IN HEALTH AND DISEASE

This research will develop cutting-edge computational tools and statistical methods to analyse, model and visualise the way in which the hum..

NEUROBIOLOGICAL 'RISK' AND 'RESILIENCE' BIOMARKERS OF SEVERE MENTAL ILLNESS

Mental disorders of childhood (schizotypal disorder, autism spectrum disorders) and adolescence (psychoses, schizophrenia) represent a major..

Using brain imaging to distinguish amongst subtypes of schizophrenia: An investigation of brain muscarinic receptors.

RESEARCH FELLOWSHIP - PROF CHRISTOS PANTELIS

I have established and head the Melbourne Neuropsychiatry Centre within the University of Melbourne. My university position is a research ch..

Grants

Awarded by Brain and Behavior Research Foundation

Funding Acknowledgements

Dr. Cropley was supported by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (628880), a Brain and Behavior Research Foundation (NARSAD) Young Investigator Award (21660), and a University of Melbourne Faculty of Medicine, Dentistry, and Health Sciences Research Fellowship. Dr. Klauser was supported by the Swiss National Science Foundation (SNSF), by the Swiss Society for Medicine and Biology Scholarships (148384), and by the National Center for Competence in Research (SYNAPSY), founded by SNSF. Dr. Bousman was supported by a University of Melbourne Ronald Phillip Griffith Fellowship and by a Brain and Behavior Research Foundation (NARSAD) Young Investigator Award (20526). Dr. Pereira was supported by the One-in-Five Association and the AMP Foundation. Ms. Di Biase was supported by an Australian Rotary Health, Ian Scott, Ph.D., Scholarship in Mental Health. Dr. Pantelis was supported by an NHMRC Senior Principal Research Fellowship (628386 and 1105825) and by a Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Award. Dr. Cynthia Shannon Weickert was supported by an NHMRC Senior Research Fellowship (1021970), the Schizophrenia Research Institute (using infrastructure from the New South Wales Ministry of Health and the Macquarie Group Foundation), the University of New South Wales, and Neuroscience Research Australia. Dr. Zalesky was supported by an NHMRC Fellowship (1047648).Data for this study were provided by the Australian Schizophrenia Research Bank (ASRB), which is supported by the National Health and Medical Research Council of Australia (enabling grant 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. The authors thank the chief investigators and manager of the ASRB: Carr V, Schall U, Scott R, Jablensky A, Mowry B, Michie P, Catts S, Henskens F, Pantelis C, and Loughland C. The authors acknowledge the help of Jason Bridge for ASRB database queries.Dr. Sundram has received consulting fees, advisory board fees, research support, speakers honoraria, or travel support from AstraZeneca, the Australian National Health and Medical Research Council, the Australian Department of Immigration and Border Protection, Bristol-Myers Squibb, Eli Lilly, the Flack Trust, GlaxoSmithKline, Lundbeck, the One-in-Five Association, Otsuka, Pfizer, Roche, and the United Nations High Commissioner for Refugees. Dr. Cynthia Shannon Weickert is on an advisory board for and has received advisory board fees from Lundbeck. Over the last 4 years, Dr. Pantelis has been on advisory boards for AstraZeneca, Janssen-Cilag, Lundbeck, and Servier; and he has received honoraria for talks presented at educational meetings organized by AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, and Shire. The other authors report no financial relationships with commercial interests.